On the other hand, in other studies using Infliximab [35] (TNF-α antagonist) and Tocilizumab [37] (Interleukin-6 signal inhibitor) as treatment, there are significant differences between the weights of the NEC group and the NEC and treatment group, with a p-value of p<0.001 and p<0.0001 respectively. The gene discussed is TNF; the disease is necrotizing enterocolitis.